Victor Paulus - Fusion Pharmaceuticals VP Affairs
Insider
Victor Paulus is VP Affairs of Fusion Pharmaceuticals
| Phone | 289 799 0891 |
| Web | https://www.fusionpharma.com |
Fusion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2334) % which means that it has lost $0.2334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4711) %, meaning that it created substantial loss on money invested by shareholders. Fusion Pharmaceuticals' management efficiency ratios could be used to measure how well Fusion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Fusion Pharmaceuticals currently holds 50.33 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Fusion Pharmaceuticals has a current ratio of 17.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Fusion Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Louise Kooij | NewAmsterdam Pharma | 49 | |
| Richard Hameister | Coherus BioSciences | N/A | |
| David MD | Passage Bio | N/A | |
| Karen Kotz | Coherus BioSciences | N/A | |
| David Mack | Pmv Pharmaceuticals | 63 | |
| Kevin MBA | Bicycle Therapeutics | 57 | |
| Lina Gugucheva | NewAmsterdam Pharma | 37 | |
| Richard Waldron | Bioatla | 71 | |
| James Brady | Spero Therapeutics | N/A | |
| Annie Neild | NewAmsterdam Pharma | N/A | |
| Leila MD | Pmv Pharmaceuticals | 61 | |
| Andy Meyer | Janux Therapeutics | 41 | |
| Byron JD | Janux Therapeutics | 60 | |
| Eric MD | Bioatla | 61 | |
| Mark Gowland | Fennec Pharmaceuticals | N/A | |
| John Moriarty | Olema Pharmaceuticals | 56 | |
| MBA MBA | Bicycle Therapeutics | 43 | |
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| William Ho | RAPT Therapeutics | 58 | |
| Edith MD | Bolt Biotherapeutics | 67 | |
| Cyrus Harmon | Olema Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 |
Fusion Pharmaceuticals Leadership Team
Elected by the shareholders, the Fusion Pharmaceuticals' board of directors comprises two types of representatives: Fusion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fusion. The board's role is to monitor Fusion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Fusion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fusion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Leamon, Chief Officer | ||
| John Valliant, CEO Founder | ||
| Mohit Rawat, President Officer | ||
| Eric Hoffman, Senior Development | ||
| Dmitri MD, Chief Officer | ||
| Maria Stahl, Chief Officer | ||
| Victor Paulus, VP Affairs | ||
| Cara Ferreira, Chief Staff | ||
| Joanne Schindler, Executive Development | ||
| Eric Burak, Chief Officer | ||
| John CPA, Chief Officer | ||
| Amanda Cray, Senior Communications |
Fusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fusion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (54.04) % | |||
| Current Valuation | 1.69 B | |||
| Shares Outstanding | 85.06 M | |||
| Shares Owned By Insiders | 0.46 % | |||
| Shares Owned By Institutions | 86.80 % | |||
| Number Of Shares Shorted | 3.06 M | |||
| Price To Book | 8.13 X | |||
| Price To Sales | 874.50 X |
Pair Trading with Fusion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fusion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fusion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to PulteGroup could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PulteGroup when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PulteGroup - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PulteGroup to buy it.
The correlation of PulteGroup is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PulteGroup moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PulteGroup moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PulteGroup can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |